Answers are grounded in this paper and cite their sources.
We identified a highly suppressive subset of regulatory T cells in the liver, defined as TIGIT⁺CD39⁺CTLA-4⁺Tregs. TIGIT agonists and IL-2 enhanced the suppressive function of this cell subset. The TIGIT ligand, CD155, is expressed on inflamed hepatocytes, and TIGIT blockade in oncology could instigate checkpoint inhibitor induced liver injury (CHILI). These findings have implications for future therapy in liver disease.
No takes yet. Share an insight, caveat, or question.
Bozward et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: